Understanding the benefits of tirzepatide beyond weight loss includes recognizing its kidney-protective properties, but this does not eliminate the need for monitoring
(production batch No: Y1H130802)
Seven developed NAION One developed a stroke in the retina (paracentral acute middle maculopathy) One developed swelling in both optic nerves (bilateral papillitis) 12.01.24 DVT, blood clot cases excluded from GLP-1 MDL Deep vein thrombosis and blood clot cases will be excluded injuries in the GLP-1 RA MDL
8.3 Inter-individual variability, non-responders, atypical responses, and endpoint-dependent effects Although GLP-1RAs show broadly consistent weight-loss efficacy at the population level, their effects on eating experience appear to vary substantially between individuals (71, 72)
These include: Dulaglutide (Trulicity) : Once-weekly injection with a single-dose pen featuring an automatic injection mechanism Semaglutide (Ozempic) : Once-weekly administration with dose escalation from 0.25 mg to maintenance doses of 0.5 mg, 1 mg, or 2 mg Exenatide extended-release (Bydureon BCise) : Once-weekly microsphere suspension requiring resuspension before injection Liraglutide (Victoza) : Once-daily injection available in a multi-dose pen For weight management, semaglutide 2.4 mg (Wegovy) and liraglutide 3.0 mg (Saxenda) are specifically FDA-approved
